Asymchem Laboratories (Tianjin) Co., Ltd. Class H (HK:6821)
:6821
Want to see HK:6821 full AI Analyst Report?
6821 Stock Chart & Stats
HK$73.80
-HK$0.50(-1.06%)
At close: 4:00 PM EST
HK$73.80
-HK$0.50(-1.06%)
Day’s Range― - ―
52-Week RangeHK$58.90 - HK$116.60
Previous CloseN/A
Volume191.84K
Average Volume (3M)640.69K
Market Cap
HK$47.97B
Enterprise ValueHK$33.09B
Total Cash (Recent Filing)HK$7.78B
Total Debt (Recent Filing)HK$238.99M
Price to Earnings (P/E)23.8
Beta1.46
Next Earnings
Sep 01, 2026Next Dividend Ex-DateN/A
Dividend Yield1.57%
Share Statistics
EPS (TTM)3.08
Shares Outstanding27,834,510
10 Day Avg. Volume442,016
30 Day Avg. Volume640,687
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)1.29
Price to Sales (P/S)3.40
P/FCF Ratio165.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$127.54Price Target Upside72.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)4.44
Revenue Forecast (FY)HK$9.22B
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetExtremely low leverage gives Asymchem durable financial flexibility: it can fund capex, scale GMP capacity, and absorb project timing without relying on costly external financing. Strong equity base improves credibility with large pharma partners over multiple quarters.
Healthy Gross And Net MarginsSustained gross margin (~42%) and mid-teens net margin reflect efficient chemical processes and pricing power in CDMO services. Durable margins support reinvestment in process development and quality systems, helping protect returns even as revenue growth normalizes.
CDMO Model With Recurring Commercial Supply PotentialThe fee-based CDMO model spans development to commercial supply, creating a pipeline of project fees plus the potential for recurring commercial contracts. This structural customer-stickiness and diversified service mix support multi-period revenue visibility and long-term client relationships.
Bears Say
Weak Cash Conversion / Thin Free Cash FlowThin FCF relative to net income and negative FCF growth reduce the company's ability to self-fund capacity expansions or cushion uneven project billing. Persistent weak cash conversion can force trade-offs between capex, working capital and shareholder returns over the medium term.
Profitability Well Below 2022–2023 PeakA pronounced step-down from peak margins implies structural margin pressure or less favorable project mix. Sustained lower profitability reduces ROE and limits the company’s ability to generate excess cash for strategic investments or to compete on pricing long-term.
Post-peak Revenue Momentum / Modest Recent GrowthSlower top-line momentum weakens utilization-driven operating leverage in capital-intensive CDMO operations. If the company cannot rekindle stronger contract wins or commercial supply rollouts, underused capacity could pressure margins and delay returns on recent investments.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H News
6821 FAQ
What was Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price range in the past 12 months?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H lowest stock price was HK$58.90 and its highest was HK$116.60 in the past 12 months.
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap is HK$47.97B.
When is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date is Sep 01, 2026 which is in 103 days.
How were Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s earnings last quarter?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H released its earnings results on Apr 27, 2026. The company reported HK$0.963 earnings per share for the quarter, beating the consensus estimate of HK$0 by HK$0.963.
Is Asymchem Laboratories (Tianjin) Co., Ltd. Class H overvalued?
According to Wall Street analysts Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price is currently Undervalued.
Does Asymchem Laboratories (Tianjin) Co., Ltd. Class H pay dividends?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H pays a Annually dividend of HK$1.202 which represents an annual dividend yield of 1.57%. See more information on Asymchem Laboratories (Tianjin) Co., Ltd. Class H dividends here
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate is 0.
How many shares outstanding does Asymchem Laboratories (Tianjin) Co., Ltd. Class H have?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H has 27,834,510 shares outstanding.
What happened to Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price movement after its last earnings report?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H reported an EPS of HK$0.963 in its last earnings report, beating expectations of HK$0. Following the earnings report the stock price went up 5.634%.
Which hedge fund is a major shareholder of Asymchem Laboratories (Tianjin) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6821
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.63%
12-Months-Change
Fundamentals
Return on Equity
6.34%
Trailing 12-Months
Asset Growth
12.62%
Trailing 12-Months
Company Description
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization services in Mainland China and internationally. The company offers drug research and development, and manufacturing services for pharmaceutical and biotech companies. Its solutions range from early clinical stage to commercial stage, including research and development, and cGMP production of advanced intermediates, active pharmaceutical ingredients, and formulations, as well as clinical research services. The company also engages in the provision of pharmaceutical analysis and testing services; sale, wholesale, and retail of drugs; and pharmaceutical science and technology development activities. The company was founded in 1999 and is headquartered in Tianjin, China.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (6821) Earnings & Revenues
6821 Stock 12 Month Forecast
Average Price Target
HK$127.54
▲(72.82% Upside)
Technical Analysis
Genscript Biotech
―
Pharmaron Beijing Co., Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---